Journal Watch · Proceedings of the National Academy of Sciences (PNAS) · 2026

Splicing suppression alters the <i>STING</i> transcription start site to attenuate antiviral innate immunity.

Given the evolutionary conservation of splicing mechanisms and STING-like pathways, this mechanism may represent a broadly applicable regulatory principle in immune defense across species.

Xu J, Liao Q, Wang J et al.Proceedings of the National Academy of Sciences (PNAS)3 min readPharma relevance 50/100

DOI: 10.1073/pnas.2613025123PMID: 42776761Study type: research study

TL;DR

Given the evolutionary conservation of splicing mechanisms and STING-like pathways, this mechanism may represent a broadly applicable regulatory principle in immune defense across species.

Key findings

  • Such a shift diverts <i>STING</i> expression from a functional antiviral isoform to a nonantiviral variant that partially suppresses STING activity, thereby disabling the cGLR-STING pathway.
  • Our findings uncover an unconventional viral immune evasion strategy and an unexpected link between splicing suppression and STING-mediated antiviral response.
  • Given the evolutionary conservation of splicing mechanisms and STING-like pathways, this mechanism may represent a broadly applicable regulatory principle in immune defense across species.

What they did

Here, we show that an insect picorna-like virus CrPV (Cricket Paralysis virus) inhibits STING-mediated antiviral activity by altering the transcription start site of <i>STING</i>. Mechanistically, CrPV infection down-regulates several spliceosomal genes and disrupts pre-mRNA splicing. This splicing impairment is sufficient to stall RNA polymerase II in transcriptional initiation condensates, reduce global transcription efficiency, and reprogram the transcription start site of <i>STING</i>.

Full abstract (original)

Background: The cGAS (cyclic GMP-AMP synthase)-STING (Stimulator of interferon genes) pathway plays a central role in antiviral innate immunity in vertebrates. Recent studies have shown that invertebrates possess a related cGLR (cGAS-like receptor)-STING pathway. However, due to the lack of direct evidence demonstrating viral evasion of cGLR-STING-mediated immunity, the functional importance of cGLR-STING pathway in antiviral responses remains uncertain in invertebrates.

What they did: Here, we show that an insect picorna-like virus CrPV (Cricket Paralysis virus) inhibits STING-mediated antiviral activity by altering the transcription start site of <i>STING</i>. Mechanistically, CrPV infection down-regulates several spliceosomal genes and disrupts pre-mRNA splicing. This splicing impairment is sufficient to stall RNA polymerase II in transcriptional initiation condensates, reduce global transcription efficiency, and reprogram the transcription start site of <i>STING</i>.

Results & conclusions: Such a shift diverts <i>STING</i> expression from a functional antiviral isoform to a nonantiviral variant that partially suppresses STING activity, thereby disabling the cGLR-STING pathway. Our findings uncover an unconventional viral immune evasion strategy and an unexpected link between splicing suppression and STING-mediated antiviral response. Given the evolutionary conservation of splicing mechanisms and STING-like pathways, this mechanism may represent a broadly applicable regulatory principle in immune defense across species.

Abstract © the authors / Proceedings of the National Academy of Sciences (PNAS) (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1073/pnas.2613025123 · PubMed 42776761.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Proceedings of the National Academy of Sciences (PNAS) study find?

Given the evolutionary conservation of splicing mechanisms and STING-like pathways, this mechanism may represent a broadly applicable regulatory principle in immune defense across species.

What type of study is this?

It is a research study, published in Proceedings of the National Academy of Sciences (PNAS) in 2026. Here, we show that an insect picorna-like virus CrPV (Cricket Paralysis virus) inhibits STING-mediated antiviral activity by altering the transcription start site of <i>STING</i>.

Where can I read the original paper?

The original is at the publisher via DOI 10.1073/pnas.2613025123. PubMed ID: 42776761. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Xu J, Liao Q, Wang J et al.. Splicing suppression alters the &lt;i&gt;STING&lt;/i&gt; transcription start site to attenuate antiviral innate immunity.. Proceedings of the National Academy of Sciences (PNAS) (2026). DOI: 10.1073/pnas.2613025123.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/splicing-suppression-alters-the-lt-i-gt-sting-lt-i-gt-transcription-star-025123/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides